Skip to main content

Advertisement

SpringerLink
Log in

The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background: Tumour growth is dependent on angiogenesis. Antiangiogenic chemotherapy, i.e. continuous or metronomic low-dose chemotherapy, is a method for administrating cytostatics at a low and well-tolerated concentration without prolonged breaks. The target is the genetically stable endothelial cells playing a pivotal role in angiogenesis within the tumour. Different mediators could mediate the antiangiogenic effect of metronomic chemotherapy. One of these mediators could be thrombospondin (TSP). TSP is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth. This study was designed to evaluate the effects of low-dose continuous or moderate-dose bolus chemotherapy on tumour growth and on tumour expression of TSP. Materials and methods: Rats bearing a malignant prostate tumour (Dunning AT-1) not expressing TSP were treated systemically with cyclophosphamide, doxorubicin or paclitaxel and the combination of cyclophosphamide and doxorubicin. Tumour growth and body weight were measured during the treatment. CD36, one of TSP’s main receptors, was also analysed. The expression pattern of TSP-1, TSP-2 and CD36 was investigated using immunohistochemistry and Western blot analyses. Q-PCR was used to analyse TSP-1 mRNA expression. Results: Low-dose cyclophosphamide and paclitaxel re-induced the expression of TSP in the tumours. However, following a bolus dose of doxorubicin, tumours showed no expression of TSP. Both cyclophosphamide and doxorubicin treatments decreased the tumour weight by more than 60% compared with vehicle controls. When cyclophosphamide and doxorubicin were combined the tumour weight was reduced by 47%, while paclitaxel reduced the tumour weight by 18% compared to the vehicle controls. Conclusions: Systemic low-dose continuous treatment of a rat prostate cancer model with cyclophosphamide and paclitaxel induced the expression of TSP in tumour tissue and inhibited tumour growth. These findings support the hypothesis that the anti-tumour effect of low-dose metronomic chemotherapy, at least with certain chemotherapeutics, is partly mediated by induction of endogenous antiangiogenic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19(4):1195–1206

    PubMed  CAS  Google Scholar 

  2. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60(5):1388–1393

    PubMed  CAS  Google Scholar 

  3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886

    PubMed  CAS  Google Scholar 

  4. Bergers G, Hanahan D (2002) Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 67:293–300

    Article  PubMed  CAS  Google Scholar 

  5. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100(22):12917–12922

    Article  PubMed  CAS  Google Scholar 

  6. Lawler J (2000) The functions of thrombospondin-1 and -2. Curr Opin Cell Biol 12(5):634–640

    Article  PubMed  CAS  Google Scholar 

  7. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J et al (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64(5):1570–1574

    Article  PubMed  CAS  Google Scholar 

  8. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP (2001) Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49(4):293–305

    Article  PubMed  CAS  Google Scholar 

  9. Kwak C, Jin RJ, Lee C, Park MS, Lee SE (2002) Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 89(3):303–309

    Article  PubMed  CAS  Google Scholar 

  10. Vallbo C, Wang W, Damber JE (2004) The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 93(9):1339–1343

    Article  PubMed  CAS  Google Scholar 

  11. Vallbo C, Damber J-E (2005) Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the dunning prostate cancer model. Acta Oncol 44(3):293–298

    Article  PubMed  CAS  Google Scholar 

  12. Lennernas B, Albertsson P, Damber JE, Norrby K (2004) Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 112(3):201–209

    Article  PubMed  Google Scholar 

  13. Isaacs JT, Isaacs WB, Feitz WF, Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9(3):261–281

    Article  PubMed  CAS  Google Scholar 

  14. Lennernas B, Albertsson P, Lennernas H, Norrby K (2003) Chemotherapy and antiangiogenesis—drug-specific, dose-related effects. Acta Oncol 42(4):294–303

    Article  PubMed  CAS  Google Scholar 

  15. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K et al (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168(6):2444–2450

    Article  PubMed  CAS  Google Scholar 

  16. Albertsson P, Lennernäs B, Norrby K (2005) On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF-A. Acta Oncol (in press)

  17. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H et al (2002) Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 8(12):3910–3921

    PubMed  CAS  Google Scholar 

  18. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 59:483–489

    PubMed  CAS  Google Scholar 

  19. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3(3):219–231

    Article  PubMed  CAS  Google Scholar 

  20. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell’Agnola C, Gobbi A et al (2001) Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61(11):4341–4344

    PubMed  CAS  Google Scholar 

  21. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11):1194–1201

    Article  PubMed  CAS  Google Scholar 

  22. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T et al (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7(1):101–111

    PubMed  CAS  Google Scholar 

  23. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell’Agnola C et al (2003) Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9(1):377–382

    PubMed  CAS  Google Scholar 

  24. Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA et al (1999) Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 59(23):5875–5877

    PubMed  CAS  Google Scholar 

  25. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939–952

    Article  PubMed  CAS  Google Scholar 

  26. Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl:S8–S9

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Swedish Cancer Society, the Nilsson, Assar Gabrielsson, Maud and Birger Gustavsson and Sahlgrenska University Hospital Foundations, Sweden for financial support.

Author information

Authors and Affiliations

  1. Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, 413 45, Goteborg, Sweden

    Jan-Erik Damber & Christina Vallbo

  2. Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden

    Per Albertsson & Bo Lennernäs

  3. Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden

    Klas Norrby

Authors
  1. Jan-Erik Damber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Vallbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Per Albertsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Lennernäs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klas Norrby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan-Erik Damber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Damber, JE., Vallbo, C., Albertsson, P. et al. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58, 354–360 (2006). https://doi.org/10.1007/s00280-005-0163-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0163-8

Keywords

Search

Navigation